These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 16580767)

  • 1. Involvement of adenosine in the neurobiology of schizophrenia and its therapeutic implications.
    Lara DR; Dall'Igna OP; Ghisolfi ES; Brunstein MG
    Prog Neuropsychopharmacol Biol Psychiatry; 2006 Jun; 30(4):617-29. PubMed ID: 16580767
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic possibilities of cysteamine in the treatment of schizophrenia.
    Pae CU; Lee C; Paik IH
    Med Hypotheses; 2007; 69(1):199-202. PubMed ID: 17166669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neurobiology of schizophrenia.
    Pearlson GD
    Ann Neurol; 2000 Oct; 48(4):556-66. PubMed ID: 11026439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neurobiology of dopamine in schizophrenia.
    Guillin O; Abi-Dargham A; Laruelle M
    Int Rev Neurobiol; 2007; 78():1-39. PubMed ID: 17349856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apoptotic mechanisms in the pathophysiology of schizophrenia.
    Jarskog LF; Glantz LA; Gilmore JH; Lieberman JA
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jun; 29(5):846-58. PubMed ID: 15908096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroimaging and emerging psychotic disorders: the Melbourne ultra-high risk studies.
    Pantelis C; Velakoulis D; Wood SJ; Yücel M; Yung AR; Phillips LJ; Sun DQ; McGorry PD
    Int Rev Psychiatry; 2007 Aug; 19(4):371-81. PubMed ID: 17671870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.
    Javitt DC
    Int Rev Neurobiol; 2007; 78():69-108. PubMed ID: 17349858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alterations of dopamine and serotonin transmission in schizophrenia.
    Remington G
    Prog Brain Res; 2008; 172():117-40. PubMed ID: 18772030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibitory deficit in schizophrenia is not necessarily a GABAergic deficit.
    Lara DR
    Cell Mol Neurobiol; 2002 Jun; 22(3):239-47. PubMed ID: 12469867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurobiology of the early course of schizophrenia.
    Jindal RD; Keshavan MS
    Expert Rev Neurother; 2008 Jul; 8(7):1093-100. PubMed ID: 18590479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The dopamine system and the pathophysiology of schizophrenia: a basic science perspective.
    Goto Y; Grace AA
    Int Rev Neurobiol; 2007; 78():41-68. PubMed ID: 17349857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 15. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications.
    Gaspar PA; Bustamante ML; Silva H; Aboitiz F
    J Neurochem; 2009 Nov; 111(4):891-900. PubMed ID: 19686383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia.
    Ohara K
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):469-74. PubMed ID: 17184889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurodevelopmental animal models of schizophrenia.
    Lillrank SM; Lipska BK; Weinberger DR
    Clin Neurosci; 1995; 3(2):98-104. PubMed ID: 7583625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Schizophrenia in childhood and adolescence.
    Mala E
    Neuro Endocrinol Lett; 2008 Dec; 29(6):831-6. PubMed ID: 19112396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensory gating deficits, pattern completion, and disturbed fronto-limbic balance, a model for description of hallucinations and delusions in schizophrenia.
    Javanbakht A
    Med Hypotheses; 2006; 67(5):1173-84. PubMed ID: 16824690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exogenous nicotine normalises sensory gating in schizophrenia; therapeutic implications.
    Conway JL
    Med Hypotheses; 2009 Aug; 73(2):259-62. PubMed ID: 19328631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.